

CORRECTION

Open Access



# Correction to: ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma

Qian Chen<sup>1†</sup>, Xiao-Wei Zhou<sup>1†</sup>, Ai-Jun Zhang<sup>1\*</sup> and Kang He<sup>2\*</sup>

**Correction to: J Exp Clin Cancer Res 40, 23 (2021)**  
<https://doi.org/10.1186/s13046-020-01821-6>

Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 1; specifically in panels presented in Fig 1c, d, f and g. The corrected figure and caption are given below.

In addition, sections of the mainbody text have been corrected in light of the above. In the ‘Results’ section, under the heading ‘Highly expressed ACTN1 predicts a poor clinical outcome in HCC patients’, the following sentences have been corrected (emphasis given to affected areas):

“Immunohistochemical analysis showed that ACTN1 was highly expressed in 69.4% (132/157) of HCC patients (Fig. 1d and e).” has been corrected to: “Immunohistochemical analysis showed that ACTN1 was highly expressed in 74% (116/157) of HCC patients (Fig. 1d and e).

“As displayed in Fig. 1f, high expression of ACTN1 was positively correlated with poor overall survival (OS,  $P = 0.027$ ) in HCC.” Has been corrected to: “As

displayed in Fig. 1f, high expression of ACTN1 was positively correlated with poor overall survival (OS,  $P = 0.007$ ) in HCC.”

The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.

Published online: 12 April 2021

## Reference

1. Chen Q, Zhou XW, Zhang AJ, et al. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma. *J Exp Clin Cancer Res.* 2021;40:23 <https://doi.org/10.1186/s13046-020-01821-6>.

The original article can be found online at <https://doi.org/10.1186/s13046-020-01821-6>.

\* Correspondence: [zhaj1268@163.com](mailto:zhaj1268@163.com); [he kang929@163.com](mailto:he kang929@163.com)


<sup>†</sup>Qian Chen and Xiao-Wei Zhou contributed equally to this work.

<sup>1</sup>Reproductive Medical Center, Department of Obstetrics and Gynecology of Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, 197 Ruijin 2nd Road, Shanghai 200025, China

<sup>2</sup>Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 160 Pujian Road, Shanghai 200127, China



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 1** ACTN1 is highly expressed in HCC tissues and predicts a poor prognosis in HCC patients. **a** The mRNA expression level of ACTN1 in 20 paired HCC and NCL tissues was analyzed by real-time qPCR. **b** The protein expression level of ACTN1 in 5 paired HCC and NCL tissues. **c** Representative immunohistochemical images of ACTN1 in HCC, thrombus, NCL and normal liver tissues. Scale bar: 50  $\mu$ m. **d** Immunohistochemical staining of ACTN1 in a tissue microarray containing 157 cases of HCC samples. Scale bar: 50  $\mu$ m. **e** The expression of ACTN1 was up-regulated in 74% of HCC patients. **f-g** Kaplan-Meier curve analysis of overall survival (OS) and disease-free survival (DFS) in HCC patients based on the expression of ACTN1. **h** Kaplan-Meier curve analysis of OS in TCGA cohort based on the expression of ACTN1. **\*\*** $P < 0.01$